Primary Progressive Multiple Sclerosis (PPMS) - Disease and Drug Overview and Epidemiology

  • ID: 4432400
  • Report
  • Region: Global
  • Pharma Scroll
1 of 3

The report provides an overview of primary progressive multiple sclerosis disease in detail, highlights the PPMS epidemiology in the present scenario and in future (forecasted) as well in key geographies across the globe and elaborates on the drugs prescribed and expected to be prescribed in PPMS by physicians . The report starts with the basic definition, causes and symptoms of Multiple Sclerosis and further details the types of Multiple Sclerosis diseases.

The report elaborates on the Primary Progressive Multiple Sclerosis disease indication detailing the definition, causes, profile of a PPMS patient, symptoms of a PPMS patient, and disease progression in a PPMS patient. The report further highlights the multiple methods through which the patient can be diagnosed for PPMS. The middle part of the report consists of PPMS epidemiology and prevalence in key geographies across the globe such as the US, the UK, Germany, Italy, France, Spain and Japan. The epidemiology for PPMS indication across key geographies has been forecast to 2024.

The latter part of the report highlights the importance of factors influencing physician prescription decisions in PPMS like efficacy factors, tolerability factors, monitoring requirements and pricing factors. The report further details the drugs prescribed or expected to be prescribed in PPMS by physicians in terms of details about the formulation, molecule, mode of administration and MoA of the drugs, their patent and trial details and the expected impact of the drug in the PPMS market.

Note: Product cover images may vary from those shown
2 of 3

1. Multiple Sclerosis Definition

2. Types of Multiple Sclerosis

a. Relapsing Remitting MS

b. Secondary Progressive MS

c. Primary Progressive MS

d. Progressive Relapsing MS

3. Primary Progressive Relapsing MS Defined

4. Causes of PPMS

5. Profile of PPMS Patient

6. Symptoms of PPMS

7. Disease progression and impact on QoL

8. Disease Diagnosis

a. Disease diagnosis through symptoms

b. Disease diagnosis through medical tests

9. Disease Epidemiology

a. US Epidemiology

b. UK Epidemiology

c. Germany Epidemiology

d. Italy Epidemiology

e. France Epidemiology

f. Spain Epidemiology

g. Japan Epidemiology

10. Factors impacting a physician’s prescription decision

a. Efficacy

b. Tolerability and Safety

c. Monitoring Requirements

d. Pricing and Reimbursement

11. Disease Modifying Therapies for PPMS

a. Laquinimod

i. About the Product

ii. Patent and Trial Details

iii. Impact of Laquinimod

b. Ocrelizumab

i. About the Product

ii. Patent and Trial Details

iii. Impact of Ocrelizumab

c. Masitinib

i. About the Product

ii. Patent and Trial Details

iii. Impact of Masitinib

d. Lemtrada

i. About the Product

ii. Patent and Trial Details

iii. Impact of Lemtrada

e. Qizenday

i. About the Product

ii. Patent and Trial Details

iii. Impact of Qizenday

f. Ibudilast

i. About the Product

ii. Patent and Trial Details

iii. Impact of Ibudilast

g. Idebenone

i. About the Product

ii. Patent and Trial Details

iii. Impact of Idebenone

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll